LIRIMILAST
|
|
|
- CAS号:
- 329306-27-6
- 英文名:
- LIRIMILAST
- 英文别名:
- LIRIMILAST;BAY 19-8004;BAY 19-8004 - Lirimilast;Urea,[2-(2,4-dichlorobenzoyl)-6-[(methylsulfonyl)oxy]-3-benzofuranyl]-;UREA, N-[2-(2,4-DICHLOROBENZOYL)-6-[(METHYLSULFONYL)OXY]-3-BENZOFURANYL]-;METHANESULFONIC ACID 2-(2,4-DICHLORO-BENZOYL)-3-UREIDO-BENZOFURAN-6-YL ESTER
- 中文名:
- LIRIMILAST
- 中文别名:
- 化合物 T15766
- CBNumber:
- CB02451336
- 分子式:
- C17H12Cl2N2O6S
- 分子量:
- 443.26
- MOL File:
- 329306-27-6.mol
|
|
|
LIRIMILAST化学性质
-
沸点:
-
663.2±55.0 °C(Predicted)
-
|
-
密度:
-
1.619±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
酸度系数(pKa):
-
12.33±0.30(Predicted)
-
|
LIRIMILAST性质、用途与生产工艺
Lirimilast (BAY 19-8004) 是一种有效的，选择性的和口服活性的磷酸二酯酶 4 (PDE4) 抑制剂，IC50 值为 49 nM。Lirimilast 可用于哮喘或慢性阻塞性肺疾病 (COPD) 的研究，具有强效的抗炎特性。
In PDE4 assays Lirimilast (BAY 19-8004) is reported to be 5-fold more potent than Cilomilast and equipotent with CDP-840 using freshly prepared PDE4 from human PMNL.
Since Lirimilast (BAY 19-8004) is orally active in the guinea-pig at 3 mg/kg and, more critically, in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio. In addition Lirimilast is found to be 3-fold more potent than Cilomilast when compared in a rat model of lung neutrophilic inflammation.
LIRIMILAST
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-19672 | Lirimilast | | 1 mg | 2240元 |
| 2024/04/30 | HY-19672 | LIRIMILAST
Lirimilast | 329306-27-6 | 5mg | 4480元 |
329306-27-6, LIRIMILAST 相关搜索:
- C17H12Cl2N2O6S
- 化合物 T15766
- 329306-27-6
- BAY 19-8004 - Lirimilast
- Urea,[2-(2,4-dichlorobenzoyl)-6-[(methylsulfonyl)oxy]-3-benzofuranyl]-
- UREA, N-[2-(2,4-DICHLOROBENZOYL)-6-[(METHYLSULFONYL)OXY]-3-BENZOFURANYL]-
- METHANESULFONIC ACID 2-(2,4-DICHLORO-BENZOYL)-3-UREIDO-BENZOFURAN-6-YL ESTER
- LIRIMILAST
- BAY 19-8004